First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
Posted: 14 November 2023 Telix today announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC) therapy, TLX591 (177Lu-rosopatamab tetraxetan).…
Neuren completes Phelan-McDermid syndrome Phase 2 trial
Posted: 14 November 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that all study visits are complete in its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome (PMS). Top-line results from the trial are expected to be available…
Neuren receives Australian Growth Company of the Year Award
Posted: 14 November 2023 Neuren Pharmaceuticals (ASX: NEU) has been presented with the 2023 Australian Growth Company of the Year Award for Health and Life Sciences. Neuren CEO Jon Pilcher commented: “We were very pleased to be recognized…
A “massive leap”: New test for blood cancer funded by MBS
Posted: 13 November 2023 Peter Mac scientists have been part of a nationwide push to get an important genetic test for blood cancer funded by Medicare. Approved by the federal government earlier this year and now funded in…
The Australian names Monash University number one in research for 2024
Posted: 13 November 2023 Monash University has been named Australia’s top research institution by The Australian in its annual list of the country’s top researchers and research institutions. Of the 250 fields of academic endeavour identified by The Australian Research Magazine…
mRNA research to accelerate through new network
Posted: 13 November 2023 Peter Mac will be part of a pioneering initiative driven by Moderna to bring together key Australian medical research institutes to form a mRNA Platform Incubator Network. The mRNA Platform Incubator Network aims to…
Wearable device makes memories and powers up with the flex of a finger
Posted: 13 November 2023 Researchers have invented an experimental wearable device that generates power from a user’s bending finger and can create and store memories, in a promising step towards health monitoring and other technologies. The innovation features…
VivaZome Therapeutics presents three posters highlighting exosome purification, customisation and manufacturing at the annual ANZSEV national exosome conference
Posted: 13 November 2023 VivaZome Therapeutics Pty Ltd (“VivaZome”) is presenting three posters at the 6th annual meeting of the Australian and New Zealand Society of Extracellular Vesicles (ANZSEV) being held this week in the Barossa Valley, South…
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 9 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has successfully completed enrolment in its ATH434-201 Phase 2…
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Posted: 6 November 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the open-label safety lead-in of its integrated AIPAC-003 Phase…
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Posted: 6 November 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial…
Amplia Reports Promising Clinical Data From Phase 1B Portion of the Accent Trial in Pancreatic Cancer
Posted: 6 November 2023 Amplia Therapeutics Limited is pleased to announce the completion of the Phase 1b stage of the ongoing ACCENT clinical trial in first-line patients with advanced pancreatic cancer. A safe and well tolerated dose of…
